1734 - Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

SN

Sean Nguyen, n/a

Shionogi Inc
Carrolllton, Texas, United States
CS

Christine M. Slover, PharmD

Shionogi Inc.
Florham Park, New Jersey, United States
Dee Shortridge, PhD

Senior Director Microbiology
JMI Laboratories
North Liberty, Iowa, United States
JS

Jennifer M. Streit, BS, MT(ASCP)

Surveillance Manager
JMI Laboratories
North Liberty, Iowa, United States
RE

Roger Echols, MD

Consultant
Infectious Disease Drug Development Consulting
Easton, Connecticut, United States
MT

Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd
Toyonaka, Osaka, Japan
YY

Yoshinori Yamano, PhD (he/him/his)

Chief Scientific Officer for Infectious Diseases
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan